CRANBURY, N.J., June 4, 2015 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE Amex: PTN) - Today's FDA Advisory
Committee's recommendation for the approval of flibanserin is an
important step forward in women's health, as the decision addresses
the important need for the women living with hypoactive sexual
desire disorder, or HSDD, to have an approved treatment option.
HSDD is a medical condition marked by a lack of sexual thoughts
and desire for sexual activity, and cannot be accounted for by
another medical physical or psychiatric condition, or a
substance-like medication. It is estimated that one in 10 women may
have the signs of HSDD at some point in their life, and as such
HSDD represents a major opportunity to address a tremendous medical
need with therapies like flibanserin and bremelanotide.
Palatin Technologies is excited to continue the development of
bremelanotide, a first-in-class, as needed, melanocortin-4 receptor
agonist being studied for the treatment of HSDD in pre-menopausal
women. Bremelanotide has a novel mechanism that activates
endogenous pathways in the brain involved in creating a sexual
response. It is unique because bremelanotide is an as-needed
(not chronic), centrally-mediated medication. Studies have
shown that it starts working within 30 to 60 minutes of
administration and remains effective for approximately eight hours,
providing women with greater control and flexibility in their
Palatin Technologies is currently enrolling premenopausal women
in Phase 3 clinical trials in North
America, studying bremelanotide as an as-needed treatment
for HSDD. Interested patients can visit reconnectstudy.com for
more information about the study.
To view the original version on PR Newswire,
SOURCE Palatin Technologies, Inc.